0001875558 2026-08-20 2026-08-20 0001875558 1 2026-08-20 2026-08-20 0001875558 2 2026-08-20 2026-08-20 0001875558 3 2026-08-20 2026-08-20 0001875558 4 2026-08-20 2026-08-20 0001875558 5 2026-08-20 2026-08-20 0001875558 6 2026-08-20 2026-08-20 0001875558 7 2026-08-20 2026-08-20 0001875558 1 2026-08-20 2026-08-20 0001875558 2 2026-08-20 2026-08-20 iso4217:USD pure S-3 S-3 EX-FILING FEES 0001875558 Nuvectis Pharma, Inc. N/A 0.0001381 0.0001381 0.0001381 0.0001381 0.0001381 0.0001381 true false S-3 Nuvectis Pharma, Inc. Equity Common Stock, $0.00001 par value per share true Equity Preferred Stock, $0.00001 par value per share true Debt Debt Securities true Other Warrants true Other Units true Other Subscription Rights true false Unallocated (Universal) Shelf true 200000000.00 0.0001381 27620.00 200000000.00 27620.00 0.00 4808.81 22811.19 (a) Represents securities that may be offered and sold from time to time in one or more offerings by Nuvectis Pharma, Inc. (the "Registrant"). (b) There are being registered hereunder an indeterminate number of shares of common stock and preferred stock, an indeterminate principal amount of debt securities, an indeterminate number of warrants to purchase common stock, preferred stock or debt securities, an indeterminate number of units, and an indeterminate number of subscription rights to purchase an indeterminate number of common stock or preferred stock, from time to time, which together shall have an aggregate initial offering price not to exceed $200,000,000. If any debt securities are issued at an original issue discount, then the offering price of such debt securities shall be in such greater principal as shall result in an aggregate offering price not to exceed $200,000,000 less the aggregate dollar amount of all securities previously issued hereunder. Any securities registered hereunder may be sold separately or as units with other securities registered hereunder. The proposed maximum offering price of the securities will be determined, from time to time, by the Registrant in connection with the issuance by the Registrant of the securities registered hereunder. The securities registered hereunder also include an indeterminate number of shares of common stock and preferred stock and amount of debt securities as may be issued upon conversion of or exchange for preferred stock or debt securities that provide for conversion or exchange, upon exercise of warrants or subscription rights or pursuant to the anti-dilution provisions of any the securities registered hereunder. In addition, pursuant to Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), the shares being registered hereunder include an indeterminate number of shares of common stock and preferred stock as may be issuable with respect to the shares being registered hereunder as a result of stock splits, stock dividends or similar transactions. (c) The proposed maximum aggregate offering price reflected in the table has been estimated solely for purposes of calculating the registration fee pursuant to Rule 457(o) under the Securities Act. true Nuvectis Pharma, Inc. S-3 333-293459 2026-02-13 4808.81 Unallocated (Universal) Shelf 34821187.50 true Nuvectis Pharma, Inc. S-3 333-293459 2026-02-13 4808.81 Pursuant to Rule 415(a)(6) under the Securities Act, the securities registered pursuant to this registration statement include $34,821,187.50 of unsold securities (the "Unsold Securities") previously registered on the registrant's registration statement on Form S-3 (File No. 333-293459), which was initially filed with the Securities and Exchange Commission on February 13, 2026 (the "Prior Registration Statement") and had a proposed maximum aggregate offering price of $150,000,000. The registrant sold an aggregate of $115,178,812.50 of such securities under the Prior Registration Statement, leaving the balance of $34,821,187.50 of Unsold Securities, in respect of which the registrant paid an aggregate registration fee of $4,808.81 (calculated at the filing fee rate which was in effect at the time of the filing of the Prior Registration Statement) relating to the Unsold Securities under the Prior Registration Statement. No additional filing fee is due with respect to the Unsold Securities in connection with the filing of this registration statement. A filing fee of $22,811.19 is paid herewith in connection with the $165,178,812.50 of additional securities registered hereunder. Pursuant to Rule 415(a)(6) under the Securities Act, the offering of Unsold Securities under the Prior Registration Statement will be deemed terminated as of the date of effectiveness of this registration statement.